The mission of the Breast Cancer Program (BC) is to conduct high-impact breast cancer research through collaborations among its members and with members of other Cancer Center programs. With a portfolio of basic, translational, clinical and population-based research, BC focuses on three broad themes: Theme 1 is focused on understanding mechanisms of responsiveness to endocrine therapy. Key accomplishments in this theme include the award of a Center for Cancer Systems Biology that supported development of the first roadmap for mathematically modeling estrogen receptor signaling (Clarke). Theme 2 elucidates nutritional, environmental and genetic risk factors of breast cancer susceptibility. Noteworthy accomplishments include demonstrating the role of epigenetic modifications in establishing and maintaining transgenerational mammary cancer susceptibility in rats (Hilakivi-Clarke). Theme 3 explores clinical, therapeutic, molecular, and social factors that impact the treatment and progression of breast cancer. Key accomplishments include a study led by Swain that changed clinical practice by showing the survival benefit of adding pertuzumab to standard therapy in metastatic HER2 positive breast cancer. Led by Robert Clarke, PhD, DSc, and Claudine Isaacs, MD, the Program has 24 members representing eight Georgetown University departments and two MedStar hospitals. The Program also includes 10 breast cancer patient advocates. From 2009 to 2012, 42 therapeutic trials have accrued 231 patients. BC research is highly collaborative and interdisciplinary, and would not be possible outside of a Cancer Center that adds value through substantial institutional support ($11.6M) and access to nine state-of-the-art Shared Resources, all of which are used by BC members. Members are supported by $5.1M in peer-reviewed funding (direct cost), including $3.1 M of direct NCI funding. BC is home to three multi-investigator grants. Productivity is demonstrated by 357 cancer-related, peer-reviewed publications, of which 35% are intra- and/or interprogrammatic, the latter including collaborators from all three other Programs. 52% of publications involve external collaborations. Additional noteworthy features include: a strong junior investigator mentorship program;development of novel investigator-initiated clinical trials across MWHC and MGUH with correlative studies using cellular reprogramming and functional genomic technologies;and outreach and research initiatives in the Black and Hispanic communities within our catchment area.

Public Health Relevance

Death rates from breast cancer are higher in the Washington, DC region than elsewhere in the U.S. and mortality is greater in Black women than in any other group. Thus, BC fills a great need through its emphasis on understanding mechanisms of responsiveness and risk factors that will address some of the unique cancer-related challenges in our catchment area.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Georgetown University
United States
Zip Code
Bae, Woo Kyun; Yoo, Kyung Hyun; Lee, Ji Shin et al. (2015) The methyltransferase EZH2 is not required for mammary cancer development, although high EZH2 and low H3K27me3 correlate with poor prognosis of ER-positive breast cancers. Mol Carcinog 54:1172-80
Adams, Inez; Christopher, Juleen; Williams, Karen Patricia et al. (2015) What Black Women Know and Want to Know About Counseling and Testing for BRCA1/2. J Cancer Educ 30:344-52
Butrick, Morgan; Kelly, Scott; Peshkin, Beth N et al. (2015) Disparities in uptake of BRCA1/2 genetic testing in a randomized trial of telephone counseling. Genet Med 17:467-75
London, Laricca; Hurtado-de-Mendoza, Alejandra; Song, Minna et al. (2015) Motivators and barriers to Latinas' participation in clinical trials: the role of contextual factors. Contemp Clin Trials 40:74-80
Mays, Darren; Niaura, Raymond S; Evans, W Douglas et al. (2015) Cigarette packaging and health warnings: the impact of plain packaging and message framing on young smokers. Tob Control 24:e87-92
Zhi, Xiuling; Lin, Ling; Yang, Shaoxian et al. (2015) ?II-Spectrin (SPTBN1) suppresses progression of hepatocellular carcinoma and Wnt signaling by regulation of Wnt inhibitor kallistatin. Hepatology 61:598-612
Rush, Christina L; Darling, Margaret; Elliott, Maria Gloria et al. (2015) Engaging Latina cancer survivors, their caregivers, and community partners in a randomized controlled trial: Nueva Vida intervention. Qual Life Res 24:1107-18
Heckler, Mary Mazzotta; Riggins, Rebecca B (2015) ERR? splice variants differentially regulate cell cycle progression. Cell Cycle 14:31-45
Kim, B; Wang, S; Lee, J M et al. (2015) Synthetic lethal screening reveals FGFR as one of the combinatorial targets to overcome resistance to Met-targeted therapy. Oncogene 34:1083-93
Tong, Angie; Kelly, Scott; Nusbaum, Rachel et al. (2015) Intentions for risk-reducing surgery among high-risk women referred for BRCA1/BRCA2 genetic counseling. Psychooncology 24:33-9

Showing the most recent 10 out of 544 publications